NeuroPro Therapeutics

NeuroPro Therapeutics is a private, clinical-stage company leveraging a de-risked drug development strategy by creating novel analogs of FDA-approved loop diuretics. Its lead candidate, NPT 2042, is an NKCC antagonist being developed for epilepsy, with Phase 2 trials planned for 2024, aiming to address the significant unmet need in the 30% of patients with drug-resistant seizures. The company's platform is built on foundational research from founder Daryl Hochman, demonstrating proof of efficacy in preclinical models without the diuretic side effect. NeuroPro's mission is to redefine neurological care by improving efficacy and tolerability for a range of brain disorders.

Medicinal chemistry platform creating brain-penetrant analogs of FDA-approved loop diuretics (NKCC antagonists) to separate therapeutic neurological effects from renal diuretic effects.

NeuroPro competes in the crowded antiepileptic drug market against numerous approved therapies and novel mechanisms in development. Its differentiation hinges on the unique NKCC1 target and the promise of efficacy without cognitive side effects. It faces competition from other companies developing drugs for treatment-resistant epilepsy, including those with novel targets and gene therapies.